



Astec LifeSciences Ltd.

Date: 25th October, 2024

To,
BSE Limited
P. J. Towers, Dalal Street, Fort
Mumbai – 400 001

To,
National Stock Exchange of India Limited
Exchange Plaza, Bandra - Kurla Complex,
Bandra (East), Mumbai-400 051

Ref.: BSE Scrip Code No. "533138"

Ref.: "ASTEC"

Debt Segment NSE:
NCD-ASTEC-ISIN: INE563J08015

Sub.: Press Release

The Board of Directors of Astec LifeSciences Limited ("the Company"), at its Meeting held on **Friday, 25th October, 2024**, has approved the Unaudited Financial Results (both Standalone and Consolidated) as per Indian Accounting Standards (IND AS) for the Quarter and Half Year ended 30th September, 2024.

We enclose a copy of the Press Release and the same is being placed on the website of the Company.

Please take the above information on your records.

Thanking you,

Yours sincerely,

For Astec LifeSciences Limited

Tejashree Pradhan
Company Secretary & Compliance Officer
(FCS 7167)

Encl.: As Above



Regd. Office :
"Godrej One", 3rd Floor,
Pirojshanagar, Eastern Express Highway,
Vikhroli (East), Mumbai - 400079,
Maharashtra, India
Telephone No. : 022-22618289
Fax No. : 022-22618289
Email id : astecinfo@godrejastec.com
Website : www.godrejastec.com
CIN : L99999MH1994PLC076236

ASTEC LIFESCIENCES LIMITED

“Godrej One”, 3rd Floor, Pirojshanagar, Eastern Express Highway, Vikhroli (E), Mumbai-400079, India

CIN: L99999MH1994PLC076236

PRESS RELEASE

Mumbai, October 25, 2024: Astec LifeSciences Limited (“Astec”) has today announced its financial results for the second quarter ended September 30, 2024

FINANCIAL OVERVIEW

Q2 FY25 Financial Summary

- Consolidated total income in Q2 FY25 was ₹ 100.5 crore as compared to ₹ 111.8 crore in Q2 FY24.
- Consolidated EBITDA loss was ₹ 17.7 crore in Q2 FY25 as compared to loss of ₹ 2.4 crore in Q2 FY24.

H1 FY25 Financial Summary

- In H1 FY25, company reported consolidated total income of ₹ 170.8 crore as compared to ₹ 256.3 crore in H1 FY24.
- In H1 FY25, company reported consolidated EBITDA loss of ₹ 63.1 crore as compared to profit of ₹ 2.4 crore in H1 FY24.

HIGHLIGHTS OF FINANCIAL PERFORMANCE (Q2 FY25 and H1 FY25)

(₹ in crore)

Particulars	Q2 FY25	Q2 FY24	% Change	H1 FY25	H1 FY24	% Change
Total Income	100.5	111.8	-10.1%	170.8	256.3	-33.4%
Earnings before depreciation, interest and taxes (EBITDA)	(17.7)	(2.4)	NM	(63.1)	2.4	NM
Profit Before Tax (PBT)	(38.6)	(17.6)	NM	(100.2)	(28.6)	NM
Net Profit after tax (PAT)	(38.6)	(13.4)	NM	(78.3)	(21.6)	NM

NM: Not Measurable

CHAIRMAN’S COMMENTS

Commenting on the performance, Mr. N B Godrej, Chairman, Astec LifeSciences Limited, said:

In Q2 FY25, Astec experienced a modest improvement in volumes within the Enterprise portfolio as compared to Q2 FY24, but this positive impact was offset by lower realizations in key Enterprise products due to Chinese overcapacity and inventory destocking. This adversely impacted topline

and profitability. In addition, a cautious approach adopted by CDMO customers further exacerbated the decline in our topline and profitability compared to Q2 FY24.

Particulars (₹ Crore)	Q2 FY25	Q2 FY24	% Change	H1 FY25	H1 FY24	% Change
Category Breakdown						
Enterprise	52.3	53.9	-3.0%	92.4	111.7	-17.3%
Contract Manufacturing	46.2	56.8	-18.8%	75.5	142.0	-46.8%
Geography Breakdown						
Exports	63.4	77.6	-18.3%	94.5	172.6	-45.2%
Domestic	35.1	33.1	5.9%	73.4	81.0	-9.4%

- ENDS –

About Astec LifeSciences Limited

Astec LifeSciences Limited (Astec) was incorporated in 1994 and is engaged in the manufacturing of agrochemical active ingredients (technical), bulk, formulations and intermediate products. Astec has a healthy sales mix of both exports and domestic sales. Our exports are to over 17 countries including the United States and countries across Europe, West Asia, South East Asia and Latin America and Africa.

For more information on the Company, please log on to www.godrejastec.com

For further information, please contact:

S. Varadaraj
Godrej Agrovet Limited
Email: s.varadaraj@godrejagrovvet.com
Tel No.: +91 22 2519 4864

Mugdha Khare
Astec LifeSciences Limited
Email: mugdha.khare@godrejastec.com
Tel No.: +91 22 2519 5777

Gaurang Chotalia
Investor Relations
Email: gavlinvestors@godrejagrovvet.com /
gaurang.chotalia@godrejagrovvet.com
Tel No.: +91 22 2519 4646

Disclaimer: "Some of the statements in this communication may be 'forward looking statements' within the meaning of applicable laws and regulations. Actual results might differ substantially from those expressed or implied. Important developments that could affect the Company's operations include changes in industry structure, significant changes in political and economic environment in India and overseas, tax laws, import duties, litigation and labour relations."